Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Description

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Conditions

Hepatocellular Carcinoma, Radiation Exposure

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Condition
Hepatocellular Carcinoma
Intervention / Treatment

-

Contacts and Locations

Knoxville

University of Tennessee Medical Center, Knoxville, Tennessee, United States, 37920

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
  • * Must be able to schedule and tolerate additional PET/CT imaging following therapy
  • * Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.
  • * Patients that are not candidates for Y90 radioembolization therapy
  • * Patients that cannot tolerate additional imaging procedures following therapy
  • * Patients that cannot tolerate the additional blood draws required for this study
  • * Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Tennessee,

Dustin Osborne, PhD, PRINCIPAL_INVESTIGATOR, University of Tennessee

Christopher Stephens, MD, PRINCIPAL_INVESTIGATOR, University of Tennessee

Study Record Dates

2019-12-31